Publication
Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer
Journal Paper/Review - Apr 8, 2020
Gnesin Silvano, Prior John O, Treyer Valerie, Kaufmann Philipp A, Ametamey Simon M, Schibli Roger, Müller Cristina, Choschzick Matthias, Früh Martin, Siano Marco, Meisel Alexander, Burger Irene A, Müller Joachim, Schaefer Niklaus
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Print
Pages
Brief description/objective
BACKGROUND
The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric trial (NCT03242993) evaluating the F-AzaFol (3'-aza-2'-[F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.
MATERIAL AND METHODS
Six eligible patients presented a histologically confirmed adenocarcinoma of the lung with measurable lesions (≥ 10 mm according to RECIST 1.1). TOF-PET images were acquired at 3, 11, 18, 30, 40, 50, and 60 min after the intravenous injection of 327 MBq (range 299-399 MBq) of F-AzaFol to establish dosimetry. Organ absorbed doses (AD), tumor AD, and patient effective doses (E) were assessed using the OLINDA/EXM v.2.0 software and compared with pre-clinical results.
RESULTS
No serious related adverse events were observed. The highest AD were in the liver, the kidneys, the urinary bladder, and the spleen (51.9, 45.8, 39.1, and 35.4 μGy/MBq, respectively). Estimated patient and gender-averaged E were 18.0 ± 2.6 and 19.7 ± 1.4 μSv/MBq, respectively. E in-human exceeded the value of 14.0 μSv/MBq extrapolated from pre-clinical data. Average tumor AD was 34.8 μGy/MBq (range 13.6-60.5 μGy/MBq).
CONCLUSIONS
F-Azafol is a PET agent with favorable dosimetric properties and a reasonable radiation dose burden for patients which merits further evaluation to assess its performance.
TRIAL REGISTRATION
ClinicalTrial.gov, NCT03242993, posted on August 8, 2017.